WallStSmart

Edwards Lifesciences Corp (EW)vsKoninklijke Philips NV ADR (PHG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Koninklijke Philips NV ADR generates 194% more annual revenue ($17.83B vs $6.07B). EW leads profitability with a 17.7% profit margin vs 5.0%. PHG appears more attractively valued with a PEG of 0.36. EW earns a higher WallStSmart Score of 53/100 (C-).

EW

Buy

53

out of 100

Grade: C-

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.8
Piotroski: 2/9

PHG

Hold

49

out of 100

Grade: D+

Growth: 5.3Profit: 5.0Value: 7.3Quality: 5.3
Piotroski: 6/9Altman Z: 1.47
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

EWSignificantly Overvalued (-537.7%)

Margin of Safety

-537.7%

Fair Value

$12.44

Current Price

$82.50

$70.06 premium

UndervaluedFair: $12.44Overvalued
PHGSignificantly Overvalued (-340.5%)

Margin of Safety

-340.5%

Fair Value

$7.28

Current Price

$26.25

$18.97 premium

UndervaluedFair: $7.28Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

EW1 strengths · Avg: 8.0/10
Operating MarginProfitability
23.7%8/10

Strong operational efficiency at 23.7%

PHG4 strengths · Avg: 9.0/10
PEG RatioValuation
0.3610/10

Growing faster than its price suggests

Revenue GrowthGrowth
110.0%10/10

Revenue surging 110.0% year-over-year

Price/BookValuation
2.0x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$1.31B8/10

Generating 1.3B in free cash flow

Areas to Watch

EW4 concerns · Avg: 2.8/10
PEG RatioValuation
2.184/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

P/E RatioValuation
46.0x2/10

Premium valuation, high expectations priced in

EPS GrowthGrowth
-76.6%2/10

Earnings declined 76.6%

PHG4 concerns · Avg: 3.0/10
P/E RatioValuation
26.4x4/10

Moderate valuation

Return on EquityProfitability
7.8%3/10

ROE of 7.8% — below average capital efficiency

Profit MarginProfitability
5.0%3/10

5.0% margin — thin

EPS GrowthGrowth
-50.0%2/10

Earnings declined 50.0%

Comparative Analysis Report

WallStSmart Research

Bull Case : EW

The strongest argument for EW centers on Operating Margin. Profitability is solid with margins at 17.7% and operating margin at 23.7%. Revenue growth of 13.3% demonstrates continued momentum.

Bull Case : PHG

The strongest argument for PHG centers on PEG Ratio, Revenue Growth, Price/Book. Revenue growth of 110.0% demonstrates continued momentum. PEG of 0.36 suggests the stock is reasonably priced for its growth.

Bear Case : EW

The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 46.0x leaves little room for execution misses.

Bear Case : PHG

The primary concerns for PHG are P/E Ratio, Return on Equity, Profit Margin.

Key Dynamics to Monitor

EW profiles as a mature stock while PHG is a hypergrowth play — different risk/reward profiles.

PHG carries more volatility with a beta of 0.94 — expect wider price swings.

PHG is growing revenue faster at 110.0% — sustainability is the question.

PHG generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

EW scores higher overall (53/100 vs 49/100), backed by strong 17.7% margins and 13.3% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Edwards Lifesciences Corp

HEALTHCARE · MEDICAL DEVICES · USA

Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.

Visit Website →

Koninklijke Philips NV ADR

HEALTHCARE · MEDICAL DEVICES · USA

Koninklijke Philips NV is a healthcare technology company in North America, Greater China and internationally. The company is headquartered in Amsterdam, the Netherlands.

Want to dig deeper into these stocks?